Hikma Ventures
Hikma Ventures is the London-based corporate venture arm of Hikma Pharmaceuticals PLC, deploying a $100 million evergreen fund into digital health and life sciences startups worldwide with up to $5 million per round.
- Company typePrivate
- Founded2015
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Hikma Ventures does
Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 and headquartered in London. The firm operates an evergreen fund of $100 million to invest in innovative digital health and life sciences companies, deploying capital stage-agnostically with a preference for Series A and beyond and ticket sizes of up to $5 million per company per round. Its portfolio spans roughly 18 active companies and over 20 investments to date across drug delivery, digital therapeutics, clinical trial innovation, respiratory care, CNS, oncology, autoimmune and chronic diseases (including type II diabetes and hypertension), and overdose/abuse prevention.
The fund's core offering is strategic capital plus operational leverage from Hikma Pharmaceuticals, a FTSE 100-listed pharma group operating 58 subsidiaries across 11 countries with 29 manufacturing plants and 8 R&D centres in MENA, Europe, and North America. Portfolio companies gain access to Hikma's regulatory pathways, manufacturing infrastructure, and distribution network, while Hikma gains exposure to disruptive digital health innovations. The team is lean (Managing Director Lana Ghanem, Principal Salma Al-Zu'bi, Analyst Haya Khoury) and is augmented by an advisory board of senior pharma operators and healthcare investment bankers.
Hikma Ventures does not charge external management fees and is wholly funded by Hikma Pharmaceuticals PLC. Returns are realized exclusively through portfolio exits; six documented exits include Lemonaid Health (acquired by 23andMe), Nebula Genomics (ProPhase Labs), Pillo Health (Stanley Black & Decker), Propeller Health (ResMed), Tact.ai (Aktana), and Winterlight Labs (Cambridge Cognition). The fund does not disclose standalone revenue or financial statements, and its investment cadence of approximately two deals per year reflects a measured, thesis-driven deployment strategy rather than scale-driven fund growth.
Hikma Ventures firmographics
Firmographics- Name
- Hikma Ventures
- Legal name
- Hikma Ventures Ltd
- Website
- https://hikmaventures.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Hikma Ventures is the London-based corporate venture arm of Hikma Pharmaceuticals PLC, deploying a $100 million evergreen fund into digital health and life sciences startups worldwide with up to $5 million per round.
- Ownership category
- akta.pro rank
Hikma Ventures industry classification
Industry- Product category
- Venture Capital
- NAICS
- All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)
Keywords
Where Hikma Ventures is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Hikma Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Investment Returns: Hikma Ventures generates returns through equity investments in portfolio companies. The evergreen fund structure allows for long-term investment perspective. Returns are realized through exits (acquisitions, IPOs) and provide strategic value to parent company Hikma Pharmaceuticals by broadening offerings and tapping into digital health and life sciences opportunities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Hikma Ventures product offering
Product offeringCore offering
Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 with a $100 million evergreen fund. The firm makes equity investments in innovative digital health and life sciences companies worldwide, focusing on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Investments are stage-agnostic with a preference for Series A and beyond, with average ticket sizes up to $5 million per company per round.
Product overview
Hikma Ventures is the strategic venture capital arm of Hikma Pharmaceuticals, established in 2015 with a $100 million evergreen fund. The firm invests in innovative digital health and life sciences companies worldwide, with a focus on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. The portfolio consists of 20+ investments, including both active portfolio companies and acquired entities. Investment strategy is stage-agnostic with preference for Series A and beyond, with average ticket sizes of up to $5 million per company per round. The firm leverages Hikma's global pharmaceutical expertise and presence to drive portfolio company success.
Differentiator
Problem solved
Functional benefit
Products and services
- Hikma Ventures Portfolio Strategic venture capital investments in innovative digital health and life sciences companies worldwide, covering drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Portfolio includes approximately 18 active companies plus former portfolio companies acquired by larger firms.
Companies that use Hikma Ventures
Customer profileSegments1 record
Ideal customer profiles1 record
Hikma Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Hikma Ventures partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Hikma Ventures competitors and assessment
Company assessmentDirect peers
- Novartis Venture Fund: Corporate venture capital arm of Novartis focused on innovative therapeutics and digital health investments. Most direct comparable as a pharma CVC with similar strategic mandate and evergreen-style long-term investment horizon.
- Sanofi Ventures: Corporate venture capital arm of Sanofi investing in digital health, biotech, and life sciences companies. Highly comparable as another pharma CVC with similar stage-agnostic approach and portfolio construction strategy.
- Roche Venture Fund: Corporate venture arm of Roche focused on early-stage diagnostics, digital health, and therapeutic investments. Comparable as a European-headquartered pharma CVC with similar evergreen structure and strategic capital deployment.
- Pfizer Ventures: Corporate venture capital arm of Pfizer investing in therapeutic, diagnostic, and digital health startups. Comparable in mandate and stage preferences, with similar focus on healthcare innovation adjacencies to core pharma operations.
- Bayer Leaps by Bayer: Bayer's corporate venture arm focused on breakthrough health and agriculture technologies. Comparable as a strategic pharma CVC with similar cross-portfolio support model for portfolio companies.
- Amgen Ventures: Corporate venture arm of Amgen investing across therapeutic areas and digital health. Comparable as a US-headquartered pharma CVC with similar evergreen capital structure and strategic investment focus.
- Merck Global Health Innovation Fund: Merck's corporate venture capital fund focused on digital health, health IT, and life sciences. Comparable as a pharma CVC with evergreen fund structure and similar emphasis on strategic distribution and partnership for portfolio companies.
- Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim focused on early-stage biotech, digital health, and innovative therapeutics. Comparable as a European pharma CVC with similar evergreen structure and mission-driven investment thesis.
- GSK (CVC activities via Action Fund and others): GSK's strategic venture activities target innovative biotech and digital health opportunities. Comparable as a global pharma corporate investor with similar focus on strategic health technology adjacencies.
Broad incumbents
- Optum Ventures: Venture capital arm of Optum (UnitedHealth Group) focused on healthcare data, digital health, and care delivery innovation. Comparable as a healthcare strategic CVC investing in overlapping categories (digital therapeutics, clinical trials) but with a larger, US-focused mandate and payor-provider ecosystem advantage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Hikma Ventures social profiles
Digital presenceHikma Ventures compliance and trust
Trust signalCompliance3 records
Hikma Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hikma Ventures leadership team
Management profileNumber of profiles
Profiles12 records
Hikma Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hikma Ventures M&A and investment
M&A and investmentM&A
Investments27 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hikma Ventures
What does Hikma Ventures do?
Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 with a $100 million evergreen fund. The firm makes equity investments in innovative digital health and life sciences companies worldwide, focusing on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Investments are stage-agnostic with a preference for Series A and beyond, with average ticket sizes up to $5 million per company per round.
Is Hikma Ventures a public or private company?
Hikma Ventures is a private company. It is classified as corporate owned and is currently operating.
When was Hikma Ventures founded?
Hikma Ventures was founded in 2015. It employs 1 to 10 people.
Where is Hikma Ventures based?
Hikma Ventures is headquartered in London, United Kingdom, in the Europe region.
How does Hikma Ventures make money?
One revenue line is on record: investment Returns.
Who are Hikma Ventures's main competitors?
Direct peers on record are Novartis Venture Fund, Sanofi Ventures, Roche Venture Fund, Pfizer Ventures, Bayer Leaps by Bayer, Amgen Ventures, Merck Global Health Innovation Fund, Boehringer Ingelheim Venture Fund and GSK (CVC activities via Action Fund and others). Optum Ventures is listed as a broad incumbent.
Does Hikma Ventures have an API?
No public API is recorded for Hikma Ventures.
What industry is Hikma Ventures in?
Hikma Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 52399 and its SIC code is 6282.